N-(2-methoxyethyl)-3,3-dimethylbutanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-(2-methoxyethyl)-3,3-dimethylbutanamide
• 化学式: C₉H₁₉NO₂
• 分子量: 173.25
• InChiKey: YCGIEBWVFSECTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Oximide derivatives and their therapeutical application
  申请人：Yu Chang Jun

  公开号：US20090012091A1

  公开（公告）日：2009-01-08

  The present invention relates to a compound represented as the following Formula (I) and a pharmaceutical composition thereof wherein all substituents are as defined in the specification; and also relates to a method for treating or lessening the severity of a disease or a condition, comprising administering said compound or said pharmaceutical composition.

  本发明涉及一种表示为以下化学式（I）的化合物及其药物组合物，其中所有取代基如规范中定义；还涉及一种治疗或减轻疾病或病况严重程度的方法，包括给予该化合物或该药物组合物。
• Chain transfer agents for raft polymerization in aqueous media
  申请人：McCormick L. Charles

  公开号：US20070123670A1

  公开（公告）日：2007-05-31

  Polymers and copolymers synthesized by means that yield a narrow range of molecular weights can have different properties than polymers synthesized by conventional means. In order to obtain such polymers, however, polymerization must be controlled. One type of controlled polymerization is the reversible addition-fragmentation chain transfer (RAFT) process, which has characteristics of a living polymerization. The present invention discloses a group of dithioesters and trithioesters suitable as chain transfer agents for RAFT polymerization. The present invention also discloses RAFT polymerizations conducted in aqueous media.

  通过产生分子量窄范围的手段合成的聚合物和共聚物可能具有不同于传统手段合成的聚合物的性质。然而，为了获得这种聚合物，聚合必须受到控制。一种受控聚合的类型是可逆加成-断裂链转移（RAFT）过程，具有活性聚合的特征。本发明揭示了一组二硫代酯和三硫代酯，适用于RAFT聚合的链转移剂。本发明还揭示了在水介质中进行的RAFT聚合。
• Substituted 4-azaindoles and their use as GluN2B receptor modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US10377753B2

  公开（公告）日：2019-08-13

  Substituted 4-azaindoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

  取代的 4-氮杂吲哚作为 NR2B 受体配体。此类化合物可用于 NR2B 受体调节以及治疗由 NR2B 受体活性介导的疾病状态、紊乱和病症的药物组合物和方法中。
• Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US10617676B2

  公开（公告）日：2020-04-14

  Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

  取代的 1H-咪唑并[4,5-b]吡啶-2(3H)-酮作为 NR2B 受体配体。此类化合物可用于 NR2B 受体调节以及治疗由 NR2B 受体活性介导的疾病状态、紊乱和病症的药物组合物和方法中。
• Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US11207298B2

  公开（公告）日：2021-12-28

  Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

  取代的 1H-咪唑并[4,5-b]吡啶-2(3H)-酮作为 NR2B 受体配体。此类化合物可用于 NR2B 受体调节以及治疗由 NR2B 受体活性介导的疾病状态、紊乱和病症的药物组合物和方法中。